Video
Glaukos COO shares product updates, 2021 pipeline
Author(s):
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Related Videos
Related Content
